SSRI/SNRI

DRUG4 trials

Conditions

Depressive DisorderDepressive Disorder, MajorGeneralized Anxiety DisorderLactationPanic Disorder

Phase 3

A Long-term Comparison of Esketamine Nasal Spray Versus Quetiapine Extended Release, Both in Combination With a Selective Serotonin Reuptake Inhibitor/Serotonin-Norepinephrine Reuptake Inhibitor, in Participants With Treatment Resistant Major Depressive Disorder

CompletedNCT04338321

Janssen-Cilag International NVDepressive Disorder, Major

Start: 2020-08-21End: 2022-07-15Updated: 2025-04-29

Phase 4

Trial to Compare Time to Response in the Symptoms of Anxiety to Concomitant Treatment With Niravam™ and an SSRI or SNRI to Treatment With an SSRI or SNRI Alone in Subjects With Generalized Anxiety Disorder or Panic Disorder

CompletedNCT00266409

UCB PharmaGeneralized Anxiety Disorder, Panic Disorder

Start: 2005-10-31End: 2006-06-30Updated: 2014-10-27

Antidepressants During Pregnancy and Lactation: Pharmacokinetics and Clinical Implications

NCT01796132

Centre Hospitalier Universitaire VaudoisDepressive Disorder, Lactation

Start: 2012-08-31End: 2018-12-31Target: 500Updated: 2015-07-28

A Long-Term Extension Study for Participants With Treatment-resistant Major Depressive Disorder Who Are Continuing Esketamine Nasal Spray Treatment

CompletedNCT04829318

Janssen-Cilag Ltd.Depressive Disorder, Major

Start: 2021-04-26End: 2024-07-22Updated: 2025-09-18

British Journal of Clinical Pharmacology2026-04-01

Long-term treatment with esketamine nasal spray in patients with treatment resistant depression: Results from the ESCAPE-LTE study

European Neuropsychopharmacology2026-02-27

Improvements in health-related quality of life with esketamine nasal spray versus quetiapine extended release.

2025-10-14

Assessment of patient-reported depression severity in subpopulation of ESCAPE-TRD study: esketamine nasal spray versus quetiapine extended release for treatment-resistant depression.

2025-08-01

Improvements in functioning and workplace productivity with esketamine nasal spray versus quetiapine extended release in patients with treatment resistant depression: Findings from a 32-week randomised, open-label, rater-blinded phase IIIb study

European Neuropsychopharmacology2025-02-087 citations

Esketamine nasal spray versus quetiapine XR in adults with treatment-resistant depression: a secondary analysis of the ESCAPE-TRD randomized clinical trial

CNS Spectrums2025-01-014 citations

Estimating the benefit of esketamine nasal spray versus real-world treatment on patient-reported functional remission: results from the ICEBERG study

Frontiers in Psychiatry2024-10-073 citations

Adverse Event Duration with Esketamine Versus Quetiapine XR in Adults With Treatment-Resistant Depression: A Subgroup Analysis of ESCAPE-TRD

CNS Spectrums2024-10-01

Safety and tolerability of esketamine nasal spray versus quetiapine extended release in patients with treatment resistant depression.

2024-07-0112 citations

Esketamine nasal spray shows greater improvement in health-related quality of life over 32 weeks versus quetiapine extended release in patients with treatment resistant depression

European Psychiatry2024-04-01

Weight changes in esketamine nasal spray and quetiapine extended-release treated patients with treatment resistant depression: Results from ESCAPE-TRD study

European Psychiatry2024-04-01

Indirect adjusted comparison of 6-month clinical outcomes between esketamine nasal spray and other real-world polypharmacy treatment strategies for treatment resistant depression: results from the ICEBERG study

Frontiers in Psychiatry2023-10-316 citations

ICEBERG study: an indirect adjusted comparison estimating the long-term benefit of esketamine nasal spray when compared with routine treatment of treatment resistant depression in general psychiatry

Frontiers in Psychiatry2023-10-314 citations

Esketamine Nasal Spray versus Quetiapine for Treatment-Resistant Depression

New England Journal of Medicine2023-10-04155 citations

Esketamine Nasal Spray Improves Rate and Time to Remission Versus Quetiapine Extended Release in Subgroups of Patients With Treatment Resistant Depression and Two or Three Plus Prior Treatment Failures: Results From ESCAPE-TRD, a Randomised Phase IIIb Trial

BJPsych Open2023-07-012 citations

Esketamine nasal spray shows higher remission and response rates over 32 weeks of treatment compared with quetiapine extended-release in patients with treatment resistant depression: Results from ESCAPE-TRD, a randomised, phase IIIb clinical trial

2023-03-01

A population pharmacokinetic model for escitalopram and its major metabolite in depressive patients during the perinatal period: Prediction of infant drug exposure through breast milk

British Journal of Clinical Pharmacology2020-03-1230 citations

SSRI/SNRI

Sponsors

Conditions

Phase 3

Phase 4

Related Papers